Pharmacy-Benefit Industry Says Drug Coupons Inflate Costs
04 November 2011 - 1:17AM
Dow Jones News
Drug-company coupons that promote brand-name medicine over
cheaper alternatives could hike drug costs by $32 billion over the
next decade, according to a study from the industry that manages
pharmacy benefits.
The study adds to a debate over a system that eases the costs of
some pricey drugs on consumers, but pushes them on to employers and
health insurers.
Drug makers have used so-called co-pay cards in recent years to
give patients a break on higher payments health plans require for
expensive pills. The manufacturers say the discounts help patients
access treatment, which can lower overall health costs.
But the pharmacy-benefit industry sees something different: a
cost-inflating marketing tool that steers patients away from
less-costly drugs. The industry is raising flags over the issue as
the number of co-pay promotions skyrockets, and as Pfizer Inc.
(PFE) gears up to use co-pay cards to battle generic competition
for Lipitor, its cholesterol-lowering blockbuster.
With co-pay cards, "people get lured to high-priced drugs for no
reason," said Mark Merritt, president and chief executive of the
Pharmaceutical Care Management Association. The group represents
pharmacy-benefit managers and paid for the co-pay card study.
Health insurers and big employers hire benefit managers, known
as PBMs, to handle drug programs and control costs. The PBMs
believe co-pay cards help drug makers circumvent strategies health
plans use to encourage cost-effective treatment.
Health plans typically require lower copayments for generic
drugs as well as for branded drugs secured through deals with drug
makers, and higher copayments for expensive alternatives. This
creates an incentive for patients to fill prescriptions for cheaper
drugs, the PBM group's study says.
The co-pay coupons erase that incentive, allowing consumers to
get brand-name drugs at a lower cost to them. However, because
insurance companies and employers bear roughly two-thirds of drugs'
costs, they get hit behind the scenes with having to pay the higher
prices for branded drugs when the co-pay cards are used.
These incentives aren't allowed under the federal Medicaid and
Medicare programs or in Massachusetts, noted consulting firm
Visante, which studied the cards for the PBM association.
Visante estimated the added cost of co-pay cards by factoring in
their fast rise in popularity--the firm anticipates 15% annual
growth in prescriptions linked to co-pay cards--against government
projections Visante says don't factor in these incentives.
Drug makers, not surprisingly, have a different view of the
situation. Karl Uhlendorf, vice president of trade group
Pharmaceutical Research and Manufacturers of America, said insurers
require patients to pay a far higher share out-of-pocket for
medicines than for other health services. He said high co-pays can
cause patients to not fill prescriptions or to stop taking their
medicines, which can boost overall health costs.
"Coupons and vouchers provide an important benefit to patients
by defraying the cost of out-of-pocket payments, breaking down
barriers to access and encouraging better medication adherence,"
Uhlendorf said. He added that most companies have longstanding
financial-assistance programs to provide drugs to uninsured and
financially struggling patients.
Visante didn't factor co-pay cards for expensive specialty drugs
in its analysis, because it said co-pay programs for these drugs
don't undermine cheaper offerings the same way as other drugs.
The pharmacy-benefit managers can't easily tell when co-pay
cards are used, but can take some steps to mitigate the impact,
such as requiring use of generics first. Also, health plans can
stop covering high-priced drugs altogether. "We're seeing more of
that," said Everett Neville, chief trade relations officer at big
PBM Express Scripts Inc. (ESRX), in a recent interview.
He indicated co-pay cards are a nuisance for insurance payers,
but not a very successful tool for driving market share.
But drug makers are boosting their card offerings nonetheless.
Cleveland Research estimates there were 310 co-pay card programs in
July this year, a 260% increase from two years earlier, for a wide
variety of medicines including heartburn pills, blood-pressure
drugs and skin-care treatments.
Pfizer is set to raise the stakes when Lipitor loses U.S. market
exclusivity Nov. 30. Pfizer, which already offers a $4 co-pay card
for the drug, plans to keep the incentives going when Lipitor faces
generic competition.
Pfizer Chief Executive Ian Read said Tuesday that the incentives
aren't intended to boost overall health costs. The company has
struck deals so that insurers won't be "disadvantaged" in
reimbursing for branded Lipitor, compared with paying for its
generic equivalents--at least in the near term.
Longer term, when more generic manufacturers enter the market,
sales of branded Lipitor are likely to decline more steeply. The
economics for offering co-pay incentives will likely become tougher
then.
Still, Pfizer's effort could help frame the co-pay card debate
as other big drugs face generic competition in coming years. "It
definitely is something that both sides will learn from," Express
Script's Neville said.
-By Jon Kamp, Dow Jones Newswires; 617-654-6728;
jon.kamp@dowjones.com
-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581;
peter.loftus@dowjones.com
Medco (NYSE:MHS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medco (NYSE:MHS)
Historical Stock Chart
From Jul 2023 to Jul 2024